| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/01/2004 | US20040063614 For therapy of brain diseases |
| 04/01/2004 | US20040063610 For therapy of mammal having a transected peripheral nerve or injured spinal cord |
| 04/01/2004 | US20040063187 Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatography |
| 04/01/2004 | US20040063179 Novel potassium channel molecules and uses therefor |
| 04/01/2004 | US20040063178 Comprises enzymatic polypeptide for identifying modulators of leukocyte adhesion and treatments of inflammatory diseases l |
| 04/01/2004 | US20040063177 Generating subtilisin mutant with decreased immunogenicity for use in laundry detergents, cosmetics and textile treatment |
| 04/01/2004 | US20040063173 Hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
| 04/01/2004 | US20040063161 Compositions and method of treating Alzheimer's disease |
| 04/01/2004 | US20040063140 Methods for diagnosis of cancer using erbB-3 |
| 04/01/2004 | US20040063135 Comprises oligonucleotides for determining concentration of glucuonidase in cell culture; detection and monitoring of malignancies and metastasis; targeted drug delivery |
| 04/01/2004 | US20040063134 Novel isoforms of human pregnancy-associated protein-E |
| 04/01/2004 | US20040063131 Comprises neuroendocrine-specific proteins-like polypeptides (NSPLP) for diagnosis, prevention and treatment of neurodegenerative and cell proliferative diseases |
| 04/01/2004 | US20040063130 Comprises tyrosine kinase peptides for identifying modulators for treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 04/01/2004 | US20040063129 Comprises oligonucleotides associated with inhibition of peroxisome proliferator activated receptors (PPAR) gene activity for treating cancer, osteoporosis, diabetes and endocrine disorders; gene expression inhibition |
| 04/01/2004 | US20040063128 20 Human secreted proteins |
| 04/01/2004 | US20040063127 Comprises nuclelotide sequences coding cytokine for diagnosis, prevention and treatment of infection, hepatitis, nephritis, cancer and autoimmune diseases |
| 04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
| 04/01/2004 | US20040062797 Controlling particle sizes; high speed degradation of liposomes releasing active materials |
| 04/01/2004 | US20040062793 Protein network; wound healing agent |
| 04/01/2004 | US20040062790 Reabsorptable polyoxyethylene glycol; biodegradation, biocompatibility |
| 04/01/2004 | US20040062777 Genetic engineered polypeptides; enzyme inhibitors |
| 04/01/2004 | US20040062776 In situ administering of neurotoxins; analgesics |
| 04/01/2004 | US20040062774 Multiple epitope immunoglobulin for prevention and/or treatment of mastitis; bactericides |
| 04/01/2004 | US20040062773 Compositions for the delivery of antigens |
| 04/01/2004 | US20040062771 Clostridial toxin disease therapy |
| 04/01/2004 | US20040062769 Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A |
| 04/01/2004 | US20040062767 Genetic engineering; synergistic mixture of antibodies |
| 04/01/2004 | US20040062763 Suppression of interleukin biosynthesis; binding, complexing to antibodies; therapy for endotoxin shock |
| 04/01/2004 | US20040062761 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
| 04/01/2004 | US20040062751 Methods for inhibiting angiogenesis |
| 04/01/2004 | US20040062750 Use of mullerian inhibiting substance for treating excess androgen states |
| 04/01/2004 | US20040062749 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
| 04/01/2004 | US20040062748 Complex of active material and polyoxyethylene glycol |
| 04/01/2004 | US20040062746 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| 04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
| 04/01/2004 | US20040062722 Aerosol delivery of insulin; absorption by lung tissue; determination of glucose concentration in blood; calibrating dosage of insulin |
| 04/01/2004 | US20040062719 Carrier for drug delivery; crystal structure core with surface coating; induce crystallization of amorphous particles; hermetic sealed packages |
| 04/01/2004 | US20040062718 Particles for inhalation having sustained release properties |
| 04/01/2004 | US20040062717 Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols |
| 04/01/2004 | US20040062716 Aerosol; high speed absorption; mixture of solvent and active materials |
| 04/01/2004 | US20040060569 Surface topography method for determining effect of a botulinum toxin upon a muscle |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | DE10244842A1 Für proteinspaltende Enzyme in Form von spezifischen Proteasen kodierende Nukleinsäuresequenzen, zugehörige Polypeptide und Verwendung von allen For protein-splitting enzymes in the form of specific proteases coding nucleic acid sequences associated polypeptides and use of all |
| 04/01/2004 | DE10244453A1 Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten Inhibition of protein kinase C-alpha for the treatment of diseases |
| 04/01/2004 | CA2833202A1 Compstatin analogs with improved activity |
| 04/01/2004 | CA2767235A1 Peptides and related molecules that modulate nerve growth factor activity |
| 04/01/2004 | CA2539477A1 Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-.gamma. |
| 04/01/2004 | CA2538719A1 Gd2 ligands |
| 04/01/2004 | CA2535769A1 Polymer-linker-drug conjugates for targeted drug delivery |
| 04/01/2004 | CA2502690A1 Compstatin analogs with improved activity |
| 04/01/2004 | CA2499996A1 Triplex hairpin ribozyme |
| 04/01/2004 | CA2499643A1 Lentiviral vector-mediated gene transfer and uses thereof |
| 04/01/2004 | CA2499625A1 Methods of increasing platelet and hematopoietic stem cell production |
| 04/01/2004 | CA2499385A1 Modified adenoviral vectors for use in vaccines and gene therapy |
| 04/01/2004 | CA2499368A1 Compositions and methods for treating heart disease |
| 04/01/2004 | CA2499111A1 Collagen-based materials and methods for augmenting intervertebral discs |
| 04/01/2004 | CA2498759A1 Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
| 04/01/2004 | CA2498164A1 Functional correction of the -786c/t- variance of the human enos-gene |
| 04/01/2004 | CA2497977A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 04/01/2004 | CA2497937A1 Nuclear factor of activated t cells receptor |
| 04/01/2004 | CA2496687A1 Ghrh analogues |
| 04/01/2004 | CA2486280A1 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 04/01/2004 | CA2443463A1 Concentrate of a factor viii:c-containing von willebrand factor and the process relating thereto |
| 03/31/2004 | EP1403377A1 Consensus phytases |
| 03/31/2004 | EP1403375A2 Recombinant live avian vaccin, using avian herpes virus as vector |
| 03/31/2004 | EP1403372A2 Composition and methods for the treatment and diagnosis of cardiovascular disease |
| 03/31/2004 | EP1403371A1 Novel polypeptide and use thereof |
| 03/31/2004 | EP1403285A1 Fibroblast growth factor receptors |
| 03/31/2004 | EP1403284A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION |
| 03/31/2004 | EP1403279A1 Protein polymer having unfold activity on higher-order structure of protein |
| 03/31/2004 | EP1402913A1 Dry powder inhalation system for transpulmonary administration |
| 03/31/2004 | EP1402906A1 Synechia inhibitory material |
| 03/31/2004 | EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 03/31/2004 | EP1402902A1 Method for treatment of vascular regeneration |
| 03/31/2004 | EP1402899A1 Remedies for sepsis |
| 03/31/2004 | EP1402898A1 Use of glycoprotein for the treatment and re-epithelialisation of wounds |
| 03/31/2004 | EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
| 03/31/2004 | EP1402896A1 Green tea extract and use thereof in treating renal dysfunction |
| 03/31/2004 | EP1402889A1 Remedies for diseases caused by nonsense mutation |
| 03/31/2004 | EP1402341A1 Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents |
| 03/31/2004 | EP1402267A1 Chp for use as marker for sepsis-type inflammatory diseases |
| 03/31/2004 | EP1402266A2 Determination of risk and treatment of complications of prematurity |
| 03/31/2004 | EP1402261A1 Colon cancer antigen panel |
| 03/31/2004 | EP1402260A2 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
| 03/31/2004 | EP1402253A2 A process for the isolation of a major harmful oxidant from cigarette smoke |
| 03/31/2004 | EP1402070A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 03/31/2004 | EP1402063A1 Antisense modulation of phospholipase a2, group iia (synovial) expression |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402050A2 Methods for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gp41 fragments |
| 03/31/2004 | EP1402049A2 Production of high levels of transgenic factor viii with engineered stability, and its therapeutic uses |
| 03/31/2004 | EP1402043A1 Methods of administering vectors to synaptically connected neurons |
| 03/31/2004 | EP1402032A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 03/31/2004 | EP1402031A2 Atopy |
| 03/31/2004 | EP1402030A2 43238, a g protein-coupled receptor and uses therefor |
| 03/31/2004 | EP1402029A2 Use of inhibitors of expression or activity of p8/com1 for treating tumors |
| 03/31/2004 | EP1402028A2 Oligonucleotides for regulating the gene coding for tnf-alpha and/or genes controlled thereby and use thereof |
| 03/31/2004 | EP1402027A2 Human methyltransferase family member, 25552, and uses thereof |
| 03/31/2004 | EP1402026A2 39228, a human alcohol dehydrogenase and uses therefor |